

## Message Text

UNCLASSIFIED

PAGE 01 STATE 200669

61

ORIGIN IO-03

INFO OCT-01 ISO-00 EUR-06 /010 R

66632

DRAFTED BY: IO/HDC:LCAVANAUGH

APPROVED BY: IO/HDC:L.CAVANAUGH

EUR:MR.RENDAHL (PHONE)

----- 066221

R 101633Z OCT 73

FM SECSTATE WASHDC

TO USMISSION GENEVA

UNCLAS STATE 200669

FOLLOWING SENT ACTION SECSTATE WHITEHOUSE DEA INFO COPENHAGEN  
LONDON OSLO STOCKHOLM OCT 5 FROM PARIS REPEATED TO YOU:

QUOTE

UNCLAS PARIS 26204

EO 11652 N/A

TAGS SNAR TGEN FR TBIO

SUBJECT NAS STUDY OF OPIUM-DERIVED PHARMACEUTICALS

REF A. STATE 191700 B PARIS 17103 C PARIS 16544 (NOTAL)

WHITE HOUSE FOR SOADAP PETER BOURNE; WHITE HOUSE FOR DR. EGEBERG  
DEPT FOR S/NM WELLMAN,CSI FOR YOUNTS  
DEA FOR GARFIELD, BELK  
DEPT PASS NIH FOR DR. NORMAN REYNOLDS

1. DRS. HARRIS, COCHIN, AND ANDERSON, ACCOMPANIED BY SCIATT, MET  
ON 3 OCTOBER WITH DR. BROCARD, SECRETAIRE GENERALE DE L'ORDRE  
NATIONALE DES MEDECINS, AND ON 4 OCTOBER WITH DR. CHARLES VAILLE,  
INSPECTEUR GENERAL DE LA SANTE; M. DUMONT OF FRANCO-PAVOT; AND  
M. FRANCKFORT, PHARMACIEN INSPECTEUR DE LA SANTE, MINISTERE DE LA  
SANTE PUBLIQUE.

2. FRENCH NOTED THAT TWO OPIUM-DERIVED PHARMACEUTICALS ARE ESPECIALLY  
UNCLASSIFIED

UNCLASSIFIED

PAGE 02 STATE 200669

IMPORTANT TO CLINICAL PRACTICE IN FRANCE: PARAGORIC AND CODEINE.

VAILLE FEELS THAT PRACTICING FRENCH PHYSICIANS COULD CONCEIVABLY BE CONVINCED TO CHANGE TO SYNTHETIC SUBSTITUTES IF REPEAT IF SATISFACTORY SUBSTITUTES WERE AVAILABLE, BUT STRESSED THAT THIS CONVERSION REQUIRING AN ATTITUDINAL CHANGE BY PHYSICIANS WOULD BE VERY SLOW AND COULD CERTAINLY NOT BE DICTATED BY SUDDEN GOVERNMENTAL FIAT. TO COMPLEMENT INFORMATION PROVIDED DURING DISCUSSIONS, DR. VAILLE WILL PROVIDE GROUP, THROUGH SCIATT, MATERIALS ON ATTITUDES OF FRENCH PHYSICIANS AND ON PHARMACEUTICAL USAGE IN FRANCE. FURTHER, DR BROCARD WILL PROVIDE GROUP WITH COPY OF HANDBOOK ON NARCOTIC DRUGS BEING SUPPLIED TO EVERY PHYSICIAN IN FRANCE.

3. DR VAILLE STATED THAT FRENCH VIEW DRUG-ABUSE PREVENTION IN FOLLOWING PRIORITIES: 1) ELIMINATION OF DRUGS OF ABUSE FROM MARKET STRONG ENFORCEMENT AGAINST DRUG TRAFFICKERS AND BY STRICT REGULATION, CONTROL ON PRESCRIPTION DRUGS, 2) A POPULACE ENLIGHTENED TO DRUG-ABUSE DANGERS VIA MEDIA THEY TRUST, 3) TREATMENT AND CARE OF "EARLY" NON-ADDICTED ABUSERS, 4) CARE, CURE, AND READAPTATION OF HARDER ADDICTS. DR VAILLE NOTED THAT WHILE NO ONE IN GOF IS VERY OPTIMISTIC ABOUT CURING HARD ADDICTS, THE GOF HAS NEVERTHELESS LAUNCHED A PROGRAM OF "CURE" AND "POST-CURE" (REHABILITATION-READAPTATION) CENTERS.

4. DR VAILLE STATED THAT FRENCH ATTITUDE IN TREATING ADDICTS IS TO COMBINE PSYCHIATRIC COUNSELING WITH CLINICAL SYMPTOMATIC THERAPY. FOR EXAMPLE, A PATIENT IN A DEPRESSIVE STATE MAY BE TRESTED WITH STANDARD ANTI-DEPRESSANTS INSTEAD OF SPECIAL PHARMACEUTICALS.

5. AS PREVIOUSLY REPORTED (REF B), FRENCH ATTITUDE TOWARD METHADONE REMAINS SIGNALLY UNENTHUSIASTIC. TWO FRENCH PHYSICIANS ARE NONETHELESS CURRENTLY PERMITTED BY THE MINISTRY OF PUBLIC HEALTH TO PRESCRIBE METHADONE IN THEIR PRACTICES IN A LIMITED, REGULATED EXPERIMENTAL PROGRAM.

6. FRENCH VERY INTERESTED, HOWEVER, IN POSSIBILITY OF NARCOTIC ANTAGONISTS. DR HARRIS MADE AN OFFER TO PREPARE INFORMATION ON TESTS BEING INITIATED IN U.S. ON ANTAGONISTS, DR VAILLE ENTHUSIASTICALLY ACCEPTED OFFER.

UNCLASSIFIED

UNCLASSIFIED

PAGE 03 STATE 200669

7. DUMONT INDICATED FRENCH STILL HIGHLY OPTIMISTIC RE: BRACTEATUM-THEBAINE FUTURE POSSIBILITIES (REFTEL C)

8. TONE OF EXCHANGES MOST AMIABLE AND OPEN. IRWIN UNQUOTE KISSINGER

UNCLASSIFIED

NNN

## Message Attributes

**Automatic Decaptioning:** X  
**Capture Date:** 01 JAN 1994  
**Channel Indicators:** n/a  
**Current Classification:** UNCLASSIFIED  
**Concepts:** DRUGS, OPIUM, DRUG TREATMENT  
**Control Number:** n/a  
**Copy:** SINGLE  
**Draft Date:** 10 OCT 1973  
**Decaption Date:** 01 JAN 1960  
**Decaption Note:**  
**Disposition Action:** n/a  
**Disposition Approved on Date:**  
**Disposition Authority:** n/a  
**Disposition Case Number:** n/a  
**Disposition Comment:**  
**Disposition Date:** 01 JAN 1960  
**Disposition Event:**  
**Disposition History:** n/a  
**Disposition Reason:**  
**Disposition Remarks:**  
**Document Number:** 1973STATE200669  
**Document Source:** CORE  
**Document Unique ID:** 00  
**Drafter:** IO/HDC:LCAVANAUGH  
**Enclosure:** n/a  
**Executive Order:** N/A  
**Errors:** N/A  
**Film Number:** n/a  
**From:** STATE  
**Handling Restrictions:** n/a  
**Image Path:**  
**ISecure:** 1  
**Legacy Key:** link1973/newtext/t19731040/aaaabdle.tel  
**Line Count:** 111  
**Locator:** TEXT ON-LINE  
**Office:** ORIGIN IO  
**Original Classification:** UNCLASSIFIED  
**Original Handling Restrictions:** n/a  
**Original Previous Classification:** n/a  
**Original Previous Handling Restrictions:** n/a  
**Page Count:** 3  
**Previous Channel Indicators:**  
**Previous Classification:** n/a  
**Previous Handling Restrictions:** n/a  
**Reference:** A. STATE 191700 B PARIS 17103 C PARI, S 16544 (NOTAL)  
**Review Action:** RELEASED, APPROVED  
**Review Authority:** kelleyw0  
**Review Comment:** n/a  
**Review Content Flags:**  
**Review Date:** 05 DEC 2001  
**Review Event:**  
**Review Exemptions:** n/a  
**Review History:** RELEASED <05-Dec-2001 by bryansd0>; APPROVED <11 MAR 2002 by kelleyw0>  
**Review Markings:**

Declassified/Released  
US Department of State  
EO Systematic Review  
30 JUN 2005

**Review Media Identifier:**  
**Review Referrals:** n/a  
**Review Release Date:** n/a  
**Review Release Event:** n/a  
**Review Transfer Date:**  
**Review Withdrawn Fields:** n/a  
**Secure:** OPEN  
**Status:** NATIVE  
**Subject:** NAS STUDY OF OPIUM-DERIVED PHARMACEUTICALS  
**TAGS:** SNAR, TGEN, TBIO, FR  
**To:** GENEVA  
**Type:** TE  
**Markings:** Declassified/Released US Department of State EO Systematic Review 30 JUN 2005